Clinical trials: Neoplasms，Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
- Trial name
- ALERT-lung (NCT03445000)
- Testing
- Alectinib
- Where
- 19 sites in Belgium, Ireland and 4 more
- Volunteers
- 14 people
- Sponsor
- ETOP IBCSG Partners Foundation
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.
- Trial name
- NCT00049790
- Testing
- recombinant human Angiostatin protein, paclitaxel, carboplatin
- Where
- United States
- Sponsor
- CASI pharmaceuticals, Inc.
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Stage IV Non-small Cell Lung Cancer
Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Current therapies for Stage IV non-small cell lung cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV lung…
- Trial name
- NCT00003497
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Lung Cancer, Non-Small Cell Lung Cancer
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.
- Trial name
- CheckMate870 (NCT03195491)
- Testing
- Nivolumab
- Where
- 30 sites in China, Thailand
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with ovarian epithelial cancer, melanoma, acute myeloid leukemia, myelodysplastic syndrome, or non-small cell lung cancer.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00039091
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
- Trial name
- NCT03273790
- Where
- Japan
- Volunteers
- 939 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer
This is a Phase I study of the ALK/FAK/Pyk2 inhibitor CT-707 in patients with ALK-positive non-small cell lung cancer. The purpose of the study is to determine the MTD/RP2D of CT-707 and evaluate whether CT-707 is safe and has…
- Trial name
- NCT02695550
- Testing
- CT-707
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Centaurus Biopharma Co., Ltd.
Non-Small Cell Lung Cancer
Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)
This study is aimed to explore the antitumor activity and the safety profile of atezolizumab in pretreated advanced NSCLC patients with rare histological subtypes.
- Trial name
- CHANCE (NCT03976518)
- Testing
- Atezolizumab
- Where
- 10 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Non-Small Cell Lung Cancer
A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer
Participants with advanced non-small cell lung cancer (NSCLC) will receive a first-line treatment of Pemetrexed, Cisplatin and Bevacizumab as induction therapy followed by a maintenance treatment of Pemetrexed and Bevacizumab.
- Trial name
- NCT01004250
- Testing
- Pemetrexed, Cisplatin, Bevacizumab
- Where
- 19 sites in Denmark, Germany and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Breast Cancer
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
This is a phase 1 study to evaluate the safety, the Recommended Phase 2 Dose (RP2D), and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative…
- Conditions
- Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT03552718
- Testing
- YE-NEO-001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NantBioScience, Inc.
Advanced Non-Small Cell Lung Cancer
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
Patients who are at least 18 years of age and have a type of cancer known as advanced non-small cell lung cancer may be eligible for this study if they meet all of the inclusion/exclusion criteria.
- Trial name
- NCT00161278
- Testing
- Carboplatin, Paclitaxel, Gene expression profiling (analysis) of tumor samples
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-Small Cell Lung Cancer
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
The purpose of this study is to understand the effects (good and/or bad) of the addition of RAD001 to standard radiation and chemotherapy (cisplatin and pemetrexed) for patients with non-small cell lung cancer.
- Trial name
- RAD001 (NCT01063478)
- Testing
- RAD001 (in addition to standard radiation and chemotherapy)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Non Small Cell Lung Cancer, Ovarian Cancer
Continued Access to RXDX-105
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.
- Conditions
- Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT03784378
- Testing
- RXDX-105
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer (NSCLC)
Construction and Application Research of a Multidisciplinary Combined Exercise Management Program for Elderly Lung Cancer Patients After Surgery Based on Social Cognitive Theory
Informed Consent Form Protocol Title: Construction and Application Research of a Multidisciplinary Combined Exercise Management Program for Elderly Lung Cancer Patients After Surgery Based on Social Cognitive Theory Version…
- Trial name
- NCT07824778
- Testing
- Exercise Management for Elderly Lung Cancer Patients After Surgery Based on Social Cognitive Theory
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sir Run Run Shaw Hospital
Lung Cancer, Non-Small Cell
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
The purpose of this study was to test a potential new kind of anti-cancer treatment, called PRAME immunotherapy in resected patients with lung cancer.
- Trial name
- PEARL (NCT01853878)
- Testing
- Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A
- Where
- 39 sites in United States, Estonia and 7 more
- Volunteers
- 137 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy
The purpose of this study is to improve early detection of treatable relapse of lung cancer and thereby improve survival and quality of life for the patients.
- Trial name
- SUPE_R (NCT03740126)
- Testing
- Whole body 18F-FDG PET/CT
- Where
- 3 sites in Denmark
- Volunteers
- 750 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Immunotherapy, Chemotherapy
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
Postoperative adjuvant chemotherapy followed by immunotherapy for non-small cell lung cancer has become a new treatment recommendation, but there are still many clinical problems to be solved in postoperative adjuvant…
- Trial name
- PANORAMA (NCT05825443)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Nanfang Hospital, Southern Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.